Funding for this research was provided by:
Forskningsrådet, Nordsjællands Hospital
Received: 30 August 2019
Accepted: 15 July 2020
First Online: 24 July 2020
Ethics approval and consent to participate
: The study was approved by the Danish Health and Medicines Authority (3–3013-340/1/) and by the Danish Data Protection Agency (HIH-2013-017). Danish legislation does not require informed consent for register-based studies.
: Not applicable.
: Dr. Rohde reports personal fees from Pfizer, Boehringer Ingelheim, Solvay, GSK, Essex Pharma, MSD and Novartis for lectures including service on speaker’s bureaus outside the submitted work and personal fees from GSK for travel/accommodations/meeting expenses, outside the submitted work.Dr. Ravn reports personal fees from MSD, Abb Vie and CSL Behring as invited speaker, outside the submitted work. Dr. Ravn reports personal fees from Statens Serum Institute as data safety monitoring board member, outside the submitted work. Dr. Ravn reports non-financial research collaboration with Astellas outside the submitted work.The remaining authors declare no other conflict of interest.